Topic

VIRX

A collection of 1 issue

Viracta Therapeutics Downgraded to Neutral by Rodman & Renshaw

Viracta Therapeutics (VIRX) faces a downgrade to Neutral from Buy by Rodman & Renshaw, with a significant price target slash to $0.25 from $3.50, indicating a negative outlook.